The first experience with a mini-rating scale for the assessment of sexual dysfunction and life-satisfaction in depressed patients in the practice by Antonioli, D. et al.
 EXCLI Journal 2004;3:46-57 – ISSN 1611-2156 
received: 15. June 2004, accepted: 20. July 2004, published: 11. August 2004 
 
Original article: 
 
The first experience with a mini-rating scale for the assessment of sexual 
dysfunction and life-satisfaction in depressed patients in the practice 
 
P.-A. Fauchère1, D. Antonioli2, R. Mullor2, R. Bischof3, A. Delini-Stula4* 
 
1Clinique romande de réadaptation, Sion, Switzerland, 2Psychiatrie and Psychothèrapie 
practices, Sion, 3artebis ag, marketing research & data solutions, Basel, Switzerland, 4ADI 
International Institute for Advancement of Drug Development GmbH, Mittlerestrasse 2, 
CH-4056 Basel, Switzerland, e-mail: adelina@datacomm.ch, telephone: +41 61 263 37 70, 
fax: + 41 61 263 37 72 (*corresponding author) 
 
 
ABSTRACT 
 
Even though many scales for the assessment of sexual dysfunction have been recently 
developed, most of them are suitable rather for the research purpose in clinical trials than to 
routine interviews in a daily, private practice. We report here the first experience with a 
simple, semi-quantitative scale for parallel assessment of sexual dysfunction and life-
satisfaction (considered to globally reflect the quality of life), which was tested in depressed 
patients treated in the psychiatric, private practice setting. A combined Sexual 
Dysfunction(SD-S) and Life-Satisfaction Scale (LS-S), was constructed based on previous 
interviews with patients. Both consisted of 4-items, assumed to represent core elements of 
sexual function and individual well-being. The scales were applied to depressed patients 
treated with any of the SSRIs or with moclobemide, a reversible and selective MAO-A 
inhibitor. These two treatments were selected for testing the scales because it is known that 
SSRIs can induce or exacerbate them and moclobemide does not seem to affect them. The 
selection of treatment modality in this study was, however, entirely at the discretion of the 
physician. The assessments were done during 3 visits (at baseline, after 2 months and after 4 
months). The results of this exploratory trial, testing the applicability, acceptance and utility 
of a combined mini- SD-S- and LS-S- scale, in 62 depressed patients, showed that the scale: 
a) was simple to use and well accepted by physicians and patients, b) was  a suitable 
instrument for the practicing physician to control the success of the treatment and c) was 
sensitively assessing the presence and severity of sexual dysfunction. 
 
Key words: sexual dysfunction, life-satisfaction, sexual dysfunction scale, depression, 
SSRI, IMAO-A, moclobemide 
 
INTRODUCTION 
 
There is no controversy today about the 
considerable impact of sexual dysfunction 
on the well being and overall satisfaction 
with life of each individual. Impaired sexual 
functioning may compromise the family life 
and partnerships and cause problems of 
compliance with therapies inducing sexual 
dysfunction. Specifically, in depressed 
patients, sexual dysfunction emerging 
during treatment represent a problem. In an 
 46
epidemiological survey of over 6000 
depressed patients, 75% stated that having a 
good sexual life is fairly or very important 
to them (Baldwin and Thomas 1996). In 
another more recent survey >95% of 
depressed patients, both men and women, 
considered sexual activity as an important 
factor of their life quality when they are 
well and in remission (D. Baier personal 
communication). Further, patient’ s 
satisfaction with treatment is an increasingly 
important criterion in judging the 
appropriateness of the selected treatment 
and may decisively influence the choice of 
any drug for an outpatient in the 
practitioners settings. 
 
Systematic assessment and rough 
quantification of sexual dysfunction and 
patient’s satisfaction with the treatment are, 
to the best of our knowledge, seldom if at 
all, a part of a routine interview in the 
general practice (GP). They are not common 
even in the psychiatric practices. In the 
recent study of National DMDA 
(Depressive, Manic- Depressive 
Association) in USA, 69% of physicians 
stated that they mention possible sexual 
dysfunction problems to patients. But, more 
than 40% of patients negated any 
questioning of their sexual life by the 
physician. In the practice, however, 
particularly women, rarely spontaneously 
report sexual problems and the physicians 
frequently neglect to consider the impact 
that they may have on the success of 
treatment and patient recovery. The 
exploration of sexual life and of the 
willingness for tolerance of possible 
treatment caused dysfunction, can, however, 
provide important information about the 
appropriateness of the drug to be selected 
for the therapy. Further, systematic and 
accurate assessment of sexual functions 
during the therapy would, for instance, 
permit the physician to better distinguish the 
depression-associated loss of libido from 
drug-induced dysfunction. It would in 
addition help to prevent the non-compliance 
with the treatment with all its consequences. 
Even though several scales for the 
assessment of sexual function have been 
currently developed (McGauhey et al. 
1999), most of them are suitable rather to 
the research purposes than to everyday 
clinical practice. Many of them are either 
too lengthy to be used routinely, or are 
intrusive, particularly for the female patient. 
They are also not always constructed to suit 
to traditional attitude and cultural 
background of every population. Further, 
they are not always sufficiently sensitive to 
treatment-induced changes and, finally, they 
mostly fail to control for patient satisfaction 
with the outcome. This last point is not an 
unimportant factor of good compliance. At 
least in Switzerland, none of the sexual 
function scales has found its systematic use 
in the general practice or private psychiatric 
practices. We felt, therefore, that there is 
still a need for a simple, users friendly 
instrument that will provide an information 
to the practicing physician about the 
patient’s sexual life and life satisfaction in 
an accurate and easy to follow form. 
 
We report here our first experience with a 
semi-quantitative, mini- scale for parallel 
assessment of sexuality and life -satisfaction 
in depressed patients. The scale was 
constructed to specifically suit a routine 
check during interviews of patients in the 
general or psychiatric private practices. It 
focused on the core elements of sexual 
function and on parameters generally 
considered to be relevant for the overall 
well-being e.g. satisfaction with life of an 
individual. The items of the scale emerged 
as important and easy to understand for the 
even uneducated patient during preliminary, 
free and unstructured, interviews with 
depressed patients attending practicing 
psychiatrists. 
 
We have tested the applicability of the scale 
in depressed outpatients under treatment 
with SSRIs and moclobemide, a reversible 
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and selective MAO-A inhibitor. Sexual 
dysfunction during therapy with SSRIs is 
common and well known. In a recent review 
Hirschfield (1999) refers to an incidence 
range of 4-75%. Based on studies with more 
systematic assessment, Modell et al. (1997) 
estimated that approximately ¾ of treated 
patients experience one or more sexual 
problems when taking SSRIs. In contrast, 
moclobemide seems to be devoid of own 
deleterious effects on sexual function 
(Philipp et al. 1993, Philipp et al. 1999, 
Philipp et al. 2000). 
 
MATERIALS AND METHODS 
 
Design of the study 
This was an open, prospective, naturalistic 
(observational), non-interventional study 
carried out in 3 psychiatric private practices 
in a French-speaking part of Switzerland. 
Patients (male and female aged >18 years) 
were included into the study if they 
presented symptoms of chronic depression 
and were in need of long-term treatment 
with antidepressants. The selection of 
treatment modality (any SSRIs or 
moclobemide), as well as of the dosing 
regimen, was entirely at the discretion of the 
investigator and was guided by his clinical 
experience and routine only. Nosological 
classification of the underlying depressive 
disorder was not considered as an a priori 
inclusion/exclusion criterion. But, patients 
were excluded from the study if they 
presented any other mental condition not 
primarily diagnosed as depression by 
ICD.10 criteria. The study period was 4 
months. 
No specific restrictions of the co-medication 
were required, but the use of 
benzodiazepines was discouraged.  
Prior to the formal start of the assessments, 
patients were informed by the physician that 
their sexual behaviour will be specifically 
questioned during the a limited period of 
treatment and were instructed how to 
understand the questions. 
 
Assessments 
Besides general information about the 
patient, history of depression and previous 
treatments, following assessments were 
done at the beginning of the trial (baseline, 
Visit 1), after 2 months (Visit 2) and 4 
months (Visit 3) when the collection of data 
was formally terminated: 
 
• Life-Satisfaction (LS-S) 
The life-satisfaction scale (LS-S) was 
devised to globally record affective and 
performance-oriented life aspects by 
physician’s interview. It consisted of 4 items 
considered to be important for the patient’s 
well being and satisfaction with current life: 
1) Performance (work efficiency, pleasure, 
satisfaction with self), 2) Leisure (hobbies, 
social life, relationship with family, 
relatives, others), 3) Sexuality (enjoyment, 
interest, satisfaction) and 4) Global 
satisfaction with present state.  During the 
interview the physician asked the patient to 
appraise the importance of each item and 
the degree of his/her satisfaction with it.  
One to four points could be allocated to 
each item. For the “importance” the 
gradation was as follows: 1= not important, 
2=of little importance, 3= quite important, 
4=very important. Satisfaction scores were: 
1 = not at all satisfied 2= hardly satisfied 3= 
satisfied, 4= very satisfied. Maximum total 
score for life-satisfaction was 16. 
 
• Sexual Dysfunction (SD-S) 
Sexual dysfunction scale (SD-S) consisted 
of 4 main items, which were unrelated to the 
gender: 1) libido  2)  sexual arousal  3) 
orgasm and 4) frequency of desire for sexual 
activity. For men, the item 5) 
“erection/ejaculation” was rated in addition. 
The items were rated as present (yes) or 
absent (no) and, if present, by severity from 
“slight”=1, “moderate”=2 to “severe”=3. 
Maximum dysfunction score for both female 
and male patients was 12 and for men 15. 
The scales are presented in the Annex. 
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• Severity of depression 
In order to control for changes of depressive 
state, severity of depression was rated by 
means of the conventional Clinical Global 
Impression (CGI) 6- points scale (0= none, 
1=borderline, 2=mild, 3= moderate, 4= 
severe, 5= very severe). No other specific 
assessments of depression were included 
because the assessment of the antidepressant 
efficacy of treatments was not the objective 
of the study. 
 
At each visit (Visit 1 = Baseline, Visit 2 = 
after 2 months, Visit 3=after 4 months) the 
prescribed medication and the co-
medication were recorded and the 
compliance of the patients with treatment 
verbally inquired. 
 
Prior to the start of the study an 
investigators meeting was held in order to 
ascertain and adjust the interview (semi-
structured) technique about sexual functions 
and the assessment attitudes of the study 
participants. The investigators were 
instructed to ask ten standard questions (see 
Annex) at the beginning of the interview 
and before starting more specific 
exploration of patient’s problems and 
completion of the questionnaires.   
 
• Analysis of the results 
 
Since the primary aim of the study was not 
to validate the scale, but to first test its 
acceptance and applicability in the practice, 
the statistics applied was only explorative. 
Means and standard deviations of 
demographic variables were calculated and, 
because of the ordinal quality of scales, 
Box-Whisker Plots showing median, 
quartiles and minimum/maximum values 
were used to assess scale values and 
changes. In order, however, to get an 
estimate of the magnitude of assessed 
changes between the visits, non-parametric, 
paired Wilcoxon-test for dependent samples; 
Friedman’s ANOVA as well as Mann-
Whitney U-test were applied, if appropriate. 
 
RESULTS 
 
The results of interviews with a total of 62 
patients, completing 4 months of 
antidepressant treatment, were available for 
the analysis. Demographic characteristics of 
the patient population are given in Table 1. 
 
Table 1: Demographic characteristics of the study population 
Treatment N AGE  
Mean ± SD 
F 
% 
M 
% 
Moclobemide 28 46.1±12.4 42.9 57.1 
SSRIs 34 43.1±11.3 67.6 32.4 
All 68 44.2±11.7 59.9 41.1 
 
The patient groups were fairly balanced 
with respect to the number of patients under 
SSRIs (N=34) and moclobemide (N=28). 
There was however significant difference in 
the distribution of gender between the 
groups in that there were significantly more 
females than males in the SSRIs group 
(67% vs. 32%) whereas in the moclobemide 
group the number of males dominated (57% 
vs. 41%). This sampling error had to be 
accounted for in the analysis of the results. 
Because this gender differences could 
influence, particularly the results related to 
sexual functions, a separate analysis of the 
sexual function variables in males and 
females was performed. 
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SSRIs used for the treatment were 
paroxetine (n=9), fluvoxamine (n=3), 
fluoxetine (n=8) and citalopram (n=12) at 
usual, recommended, fixed therapeutic 
doses. The doses of moclobemide (n=28) 
were in the range between 150 to 450 
mg/daily. 
 
With respect to the severity of depression 
there was no significant difference between 
the SSRIs and moclobemide groups at 
baseline. The CGI median values were 2.7 
and 3.2 respectively. There was however a 
larger variation (25-75% quartiles II-III) in 
the SSRIs group. In the SSRIs group the 
quartiles II-III values varied between 1-4, 
whereas in the moclobemide group they 
were between 3-4. Strictly, this means that 
there were more severe cases in the 
moclobemide than in the SSRIs group (in 
which the female population dominated). 
 
There were no significant overall 
differences in other variables (LS, sexual 
dysfunction) between the groups. 
Nevertheless, the analysis of sexual 
dysfunction by gender revealed larger 
variance and lower severity of dysfunction 
in the SSRIs treated female patients when 
compared to the SSRIs treated males or to 
the male and female moclobemide groups. 
 
Life-satisfaction (LS-S) 
The life-satisfaction changed during the 
treatment. There was a clear shift to the 
greater satisfaction toward the end of study 
and the difference between initial and end 
LS-S total score in drug- groups proved to 
be highly significant (Table 2). 
 
Table 2: Changes of LS- scores during treatment 
Treatment N Baseline 
Mean ±SD 
Visit 2 
Mean ±SD 
Visit 3 
Mean ±SD 
Moclobemide 28 5.9± 2.94 6.7 ± 3.171 7.8 ± 3.931
SSRIs 34 6.8 ± 3.53 7.8 ± 3.70 8.5 ± 3.752
1p< 0.003 vs baseline, 2p< 0.002 vs baseline (Wilcoxon-paired test) 
 
There was no difference between the 
treatments with respect to achieved 
satisfaction at the end of the trial, but the 
variability of the response to moclobemide 
(revealed by Whisker-Box Plot quartiles II-
III: 25-75%) was much smaller than that to 
SSRIs. The judgement of importance of 
each life-satisfaction item showed no 
variations and changes during any 
treatment. Each item of the scale was 
consequently scored as very important by 
each patient. 
 
 
 
 
Sexual Dysfunction  Scale (SD-S) 
The analysis of the questionnaires (all 
patients) revealed overall higher severity 
and higher variability of the total scores for 
sexual dysfunction in the SSRIs group 
(females and males) then in the 
moclobemide group But, the bias of this 
result due to the imbalance of genders in the 
treatment groups had to be considered and 
therefore further analysis by gender was of 
interest. It revealed somewhat lower 
severity larger variability of the SD- scores 
in the SSRI female patients over time than 
in males (quartiles II and III, 25-75%, 
Figure 1 and 2). 
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Figure 1(left) and 2(right): Each bar represents the Box- Whisker plots 25-75% 
quartiles with minimum and maximum values of sexual dysfunction scores in 
SSRIs-treated female  (Figure 1) and male (Figure 2) patients. Each point at the 
curves represents the median SD score at visits 1-3 
 
 
The analysis of results collected in the 
moclobemide group revealed somehow 
opposite gender-related effects (Figure 3 
and 4). In female patients median SD scores 
between the visits 1 to 3 dropped visibly , 
although  the difference failed to reach 
statistical significance at 5% level 
(Friedman’s ANOVA Chi2  = 0.636, p<0.73).  
In male patients the median scores varied 
between the visits without a visible trend in 
either direction. These variations were not 
significant (Visit 1-3: Friedman’s ANOVA 
Chi2 =0.560, p<0.76). 
 
 
 
 
Severity of depression 
There was a sustained improvement of 
depression in the drug treated patients, 
which was reflected in the significant drop 
of the severity scores from one visit to the 
other (Table 3). There was no overall 
significant difference between the SSRIs 
and moclobemide with respect to the 
efficacy of treatment. 
 
Safety of treatments 
All treatments were well tolerated. In none 
of the patients the treatment had to be 
discontinued because of safety reasons. 
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Figures 3(left) and 4(right): Each bar represents the Whisker Box plot (quartiles 
25-75%) and minimum- maximum values of sexual dysfunction score in female 
(Figure 3) and male (Figure 4) patients treated with moclobemide at each visit (visit 
1-3). Each point on the curves represents the median score of sexual dysfunction at 
each visit. 
 
Table 3: Changes of the severity of depression (CGI) during treatment 
Treatment N Baseline 
Mean±SD 
Visit 2 
Mean±SD 
Visit 3 
Mean±SD 
Moclobemide 28 3.2±0.61 2.5±0.96 1.9±1.39*** 
SSRIs 34 2.7±1.26 2.3±1.12 1.5±1.36*** 
*** p<0.001 vs. Baseline (Wilcoxon paired test) 
 
DISCUSSION 
 
The main objective of this study was to 
explore the applicability of a simple, mini- 
rating scale for parallel assessment of sexual 
dysfunction (SD-S) and life-satisfaction 
(LS-S). These scales were designed with the 
purpose to suit routine use in the private 
practice setting. The study was guided by 
the assumption that: a) (feasibility) 
systematic assessment of only core-aspects 
of sexual functioning with simple, non-
intrusive, mini- scale might still provide 
sufficient guidance to physician about the 
patient’s sexual problems during drug 
treatment; b) (appropriateness and 
sensitivity) that such instruments can 
adequately measure the magnitude of 
changes during the treatment and, perhaps, 
c) (discriminative quality) be appropriate for 
the assessment of drug-drug differences.  
 
The core items of our LS- scale were 
extracted from the English versions of 
various, but widely used QoL scales (Bech 
1993), but the selection of items was 
primarily guided by clinical experience of 
the investigators with preceding interviews. 
 
The sexual dysfunction scale was 
principally similar to the questionnaire 
proposed and used by Philipp et al. (1999), 
but its elements (libido, sexual arousal, 
orgasm, frequency of the desire for sexual 
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contacts) are also almost consistently used 
in other scales. In constructing the scale we 
intended to make it independent of the 
gender, but, in retrospect, we found  that it 
was a failure not to introduce the item 
“vaginal lubrification” for female patients. 
Based on the experience from another study 
(Delini-Stula et al. 2003), we feel that this is 
an important parameter indicating the level 
of physical sexual arousal in women. We do 
intend therefore to revise the scale and 
introduce this item in the next version. 
 
In the LS-scale the rating of 4 items, 
assumed to globally reflect patient’s 
perception of the current well-being, were 
introduced primarily with the intention to 
have another dimension of the evolution of 
the patient’s state during treatment. Indeed, 
in parallel with decreasing severity of 
depression, the assessment of the patient 
satisfaction with life dramatically and 
highly significantly increased. The measure 
of life satisfaction appeared therefore to be a 
very sensitive and valuable supportive 
evidence of the therapy success. Our data, 
however,  were not suitable for a particular 
analysis of the relationship between the 
parameters of life-satisfaction and sexual 
dysfunction, which would certainly be of 
interest. 
The analysis of the results showed that the 
presence and severity of sexual dysfunction 
in our population was reflected in the 
changes of the item scores during the trial. 
The changes varied in dependence of the 
drugs and genders. This variability might 
have had different reasons, but, importantly, 
the direction of  changes in SD did not 
seems to be parallel to the improvement of 
depression. It is to note also, that in none of 
the treatment groups the changes in SD 
score have attained significance level, not 
even in the moclobemide treated female 
patients, in spite of the visibly consistent 
decrease of the severity scores between the 
visits. But, we consider here the significance 
or lack of significance of the changes during 
the treatment as meaningless for correct 
interpretation of drug effects on sexual 
functions. As stressed before, the study was 
not fully controlled, individual drug  
treatments were not identical, and the 
gender subgroup samples too small to cope 
with individual variability. The data provide 
however an important argument in favour of 
the applicability of the scale, since they 
demonstrate that it was possible to measure 
the presence of sexual dysfunction and 
individual changes of their severity during 
the treatment. 
The assessment of SD revealed gender- 
related differences tin response to drug 
treatments. Globally, in males sexual 
dysfunction persisted under both drugs. In 
female patients there was visible 
improvement of SD under moclobemide 
treatment , indicated by rather large and 
sustained drop of median severity scores 
from one visit to the other. This was, 
however, a very small sample and various 
errors (sampling error, measurement errors, 
item (mis)interpretation) can account for the 
lack of statistical significance of this result. 
We are not aware of specific gender- related 
studies of moclobemide effects on sexual 
dysfunction. It is, nevertheless, interesting 
that in a comparative study of moclobemide 
versus doxepine performed by Philipp et al. 
(1993), in which the majority of patients 
were females, group comparison showed, by 
identical antidepressant efficacy, higher 
degree of improvement of sexual 
dysfunction under moclobemide than 
doxepine. Therefore, the effect of 
moclobemide that we have observed in our 
study is perhaps worth further exploration. 
 
Irrespectively of the drug-related findings 
and limits of their interpretation, our 
combined mini-scale proved to be simple 
and user-friendly. It provided sufficient 
information to practicing physician in that: 
a) it accounted for individual changes 
during treatment in the form that b) 
permitted an adequate control of the 
treatment effects. In particular, the 
questioning was very well accepted and 
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easy to understand by patients. The only 
parameter of the scale, which in our study 
proved to be obsolete, was the rating of the 
importance of individual LS items. All the 
aspects of daily life were for our patient 
population of constant importance and this 
judgement was not influenced by patient’s 
illness. 
 
In conclusion, we feel that the findings of 
this study, exploring the applicability of 
combined, mini-, semi-quantitative scale for 
the assessment of sexual functioning and 
life-satisfaction in depressed out-patients, 
encourage further testing and validation of 
its  applicability in the practice.  
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ANNEX 
 
Life Satisfaction (LS-S) and Sexual Dysfunction Scale (SD-S) 
 
Life- Satisfaction Scale (LS-S)* 
 
 Satisfaction Importance 
 High Moderate Low Very low None Low Moderate High
 Activities and performance 
(working efficacy, pleasure and 
satisfaction with self) 
1 2 3 4 
    
 
   1            2 3 4 
      
 Free-time activities (hobbies, 
social life and family 
relationships) 
1            2  3 4 
              
 1 2 3 4 
     
 Sexual life and enjoyment 
(pleasure and interest, desire) 
1            2 3 4 
                           
 1 2 3 4 
     
 Global satisfaction  (with actual 
life)  
1            2 3 4 
                          
 1 2 3 4 
     
  Total score  ______  Total score ______ 
 
* Translation of  the French version 
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Sexual Dysfunction Scale (SD-S)* 
 
 
Do you have at present any problems with your sexual life and if  yes how severe are they? 
 
 Severity 
(degree of  impairment) 
  1=mild, 2= moderate, 3= severe 
1. Libido (sexual drive, desire ) No 
 
Yes  
 
If  yes 
 1 2 3 
    
 
 2. Initiation of  sexual act 
(ease of  sexual arousal) 
No  
Yes  
 
If  yes 
 1 2 3 
    
 
 
 3. Orgasm  
(ease of  achievement) 
No  
Yes  
 
If  yes 
 1 2 3 
    
 
 4. Frequency of  desire for sexual 
activity    
          ( frequently, rarely , not at all) 
No  
Yes  
 
If  yes 
 1 2 3 
    
 
 
TOTAL SCORE ( males & females) 
  
 
  
 
 
For men only 
5. Erection/ejaculation  
(ease, maintenance/delayed, premature) 
No  
Yes 
  
If  yes 
           1                    2                     3 
                                                      
 
TOTAL  SCORE men 
                   
*Translation of  the French version 
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Instructions for the use of Scale 
LS-S: In a collaborative interview patient is invited to rate her/his satisfaction with life with 
respect to the overall satisfaction and importance (attributed to performance, leisure 
activities and sexual life,  global life satisfaction) during the past week. A score from 1 to 4 
is used to define the degree of life-satisfaction and importance of the item. 
SF-S: After explaining the aim of the interview about the sexual life and instructing the 
patient how to understand each item, the patient is invited to specify the type of problem 
(libido, initiation, orgasm, ejaculation/erection for man, sexual intercourse 
frequency/desire) and to rate the degree of impairment ( severity)  from 1-3 points (mild-
moderate-severe). During the first visit the patient is asked: “Do you have at present any 
problems with….” In the subsequent visits the rating should consider the period since the 
last visit. 
 
Ten Key Questions to Explore the history of Sexual Dysfunction 
 
1. How do you feel about your sexual life? Do you have any problems? If yes, could 
you please describe them 
 
2. On the whole, do you experience pleasure or pleasurable feelings about sexual 
activity? (If not,  we would like to explore the reason) 
 
 
3. Do you feel that your overall desire (need) for the intimacy of sexual contacts has 
changed ? How severe is this change? 
 
4. Do you feel that  you have difficulties in getting sensually- or physically (erection, 
vaginal lubrification) aroused? If, yes could you rate the extent of the difficulty ?  
 
5. Do you have any problem in reaching the climax (orgasm)? If yes, how severe is it ?  
 
6. Have you noticed any changes in your satisfaction with orgasm? If yes, please 
describe  
 
7. (for men specifically) Have you noticed any problem with erection/ejaculation? If 
yes, please describe  
 
8. Are your sexual problems lasting or they emerge in particular situations only?  
 
9. Do you have spontaneous sexual fantasies and thoughts?  
 
10. On the whole, how satisfied are you with your sexual life? 
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